Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entresto in heart failure with reduced ejection fraction: remodeling and fibrosis study
2017-002914-30Phase 4Active
- Sponsor
- Fundación IMABIS
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sacubitril + valsartan in chronic heart failure (CHF) and heart failure with reduced ejection fraction (HFrEF), sponsored by Fundación IMABIS. Primary endpoint: Change in myocardial fibrosis mass on cardiac MRI. Started Sep 2017; status: active.
02
Drugs
sacubitril + valsartan
03
Conditions
chronic heart failure (CHF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2017-002914-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002914-30.